Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Background: New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed.

Methods: We conducted a phase 1 clinical trial to assess the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria infection in healthy adults who had never had malaria or received a vaccine for malaria. The participants received L9LS either intravenously or subcutaneously at a dose of 1 mg, 5 mg, or 20 mg per kilogram of body weight. Within 2 to 6 weeks after the administration of L9LS, both the participants who received L9LS and the control participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying (3D7 strain).

Results: No safety concerns were identified. L9LS had an estimated half-life of 56 days, and it had dose linearity, with the highest mean (±SD) maximum serum concentration (C) of 914.2±146.5 μg per milliliter observed in participants who had received 20 mg per kilogram intravenously and the lowest mean C of 41.5±4.7 μg per milliliter observed in those who had received 1 mg per kilogram intravenously; the mean C was 164.8±31.1 in the participants who had received 5 mg per kilogram intravenously and 68.9±22.3 in those who had received 5 mg per kilogram subcutaneously. A total of 17 L9LS recipients and 6 control participants underwent controlled human malaria infection. Of the 17 participants who received a single dose of L9LS, 15 (88%) were protected after controlled human malaria infection. Parasitemia did not develop in any of the participants who received 5 or 20 mg per kilogram of intravenous L9LS. Parasitemia developed in 1 of 5 participants who received 1 mg per kilogram intravenously, 1 of 5 participants who received 5 mg per kilogram subcutaneously, and all 6 control participants through 21 days after the controlled human malaria infection. Protection conferred by L9LS was seen at serum concentrations as low as 9.2 μg per milliliter.

Conclusions: In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 614 ClinicalTrials.gov number, NCT05019729.).

Citing Articles

Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs.

Frooman M, Choi K, Kahn M, Yang L, Cunningham A, RisCassi J Sci Rep. 2025; 15(1):8614.

PMID: 40074802 PMC: 11903679. DOI: 10.1038/s41598-025-92191-6.

Late killing of sporozoites in the liver by an anti-circumsporozoite protein antibody.

Aguirre-Botero M, Pacios O, Celli S, Aliprandini E, Gladston A, Thiberge J Elife. 2025; 14.

PMID: 39951341 PMC: 11828480. DOI: 10.7554/eLife.105291.

Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.

Yoo R, Jore M, Julien J Immunol Rev. 2025; 330(1):e70001.

PMID: 39907429 PMC: 11796336. DOI: 10.1111/imr.70001.

Therapeutic development to accelerate malaria control through intentional intervention layering.

Braunack-Mayer L, Nekkab N, Malinga J, Kelly S, Ansah E, Moehrle J Malar J. 2025; 24(1):12.

PMID: 39806410 PMC: 11731559. DOI: 10.1186/s12936-024-05222-4.

ProC6C, a novel multi-stage malaria vaccine, elicits functional antibodies against the minor and central repeats of the Circumsporozoite Protein in human adults.

Plieskatt J, Ofori E, Naghizadeh M, Miura K, Flores-Garcia Y, Borbye-Lorenzen N Front Immunol. 2024; 15:1481829.

PMID: 39555079 PMC: 11563800. DOI: 10.3389/fimmu.2024.1481829.

References

Seder R, Chang L, Enama M, Zephir K, Sarwar U, Gordon I . Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. DOI: 10.1126/science.1241800. View

Neafsey D, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A . Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015; 373(21):2025-2037. PMC: 4762279. DOI: 10.1056/NEJMoa1505819. View

Julien J, Wardemann H . Antibodies against Plasmodium falciparum malaria at the molecular level. Nat Rev Immunol. 2019; 19(12):761-775. DOI: 10.1038/s41577-019-0209-5. View

Gaudinski M, Berkowitz N, Idris A, Coates E, Holman L, Mendoza F . A Monoclonal Antibody for Malaria Prevention. N Engl J Med. 2021; 385(9):803-814. PMC: 8579034. DOI: 10.1056/NEJMoa2034031. View

Jongo S, Church L, Mtoro A, Chakravarty S, Ruben A, Swanson P . Safety and Differential Antibody and T-Cell Responses to the Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. Am J Trop Med Hyg. 2019; 100(6):1433-1444. PMC: 6553883. DOI: 10.4269/ajtmh.18-0835. View

Portugal S, Tipton C, Sohn H, Kone Y, Wang J, Li S . Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife. 2015; 4. PMC: 4444601. DOI: 10.7554/eLife.07218. View

Wang L, Pereira L, Flores-Garcia Y, OConnor J, Flynn B, Schon A . A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver. Immunity. 2020; 53(4):733-744.e8. PMC: 7572793. DOI: 10.1016/j.immuni.2020.08.014. View

Garver L, Dowler M, Davidson S . Controlled Human Malaria Infection at the Walter Reed Army Institute of Research: The Past, Present, and Future From an Entomological Perspective. US Army Med Dep J. 2015; :16-24. View

Kisalu N, Pereira L, Ernste K, Flores-Garcia Y, Idris A, Asokan M . Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight. 2020; 6(3). PMC: 7934869. DOI: 10.1172/jci.insight.143958. View

10.

Spring M, Polhemus M, Ockenhouse C . Controlled human malaria infection. J Infect Dis. 2014; 209 Suppl 2:S40-5. DOI: 10.1093/infdis/jiu063. View

11.

Thera M, Doumbo O, Coulibaly D, Laurens M, Ouattara A, Kone A . A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011; 365(11):1004-13. PMC: 3242358. DOI: 10.1056/NEJMoa1008115. View

12.

Oneko M, Steinhardt L, Yego R, Wiegand R, Swanson P, Kc N . Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021; 27(9):1636-1645. DOI: 10.1038/s41591-021-01470-y. View

13.

Zalevsky J, Chamberlain A, Horton H, Karki S, Leung I, Sproule T . Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010; 28(2):157-9. PMC: 2855492. DOI: 10.1038/nbt.1601. View

14.

Ishizuka A, Lyke K, DeZure A, Berry A, Richie T, Mendoza F . Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016; 22(6):614-23. PMC: 11294733. DOI: 10.1038/nm.4110. View

15.

Kisalu N, Idris A, Weidle C, Flores-Garcia Y, Flynn B, Sack B . A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018; 24(4):408-416. PMC: 5893371. DOI: 10.1038/nm.4512. View

16.

Balikagala B, Fukuda N, Ikeda M, Katuro O, Tachibana S, Yamauchi M . Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021; 385(13):1163-1171. DOI: 10.1056/NEJMoa2101746. View

17.

Mejia R, Booth G, Fedorko D, Hsieh M, Khuu H, Klein H . Peripheral blood stem cell transplant-related Plasmodium falciparum infection in a patient with sickle cell disease. Transfusion. 2012; 52(12):2677-82. PMC: 3408807. DOI: 10.1111/j.1537-2995.2012.03673.x. View

18.

. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015; 386(9988):31-45. PMC: 5626001. DOI: 10.1016/S0140-6736(15)60721-8. View